Multiple sclerosis lesions: Insights from imaging techniques

Expert Review of Neurotherapeutics

Volumn 9, Issue 9, 2009, Pages 1341-1359

  Tomassini, Valentina ^a,b   Palace, Jacqueline ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Damage; Lesion; MRI; Multiple sclerosis; Normal appearing grey matter; Normal appearing white matter; Therapy

Indexed keywords

DEMYELINATING DISEASE; HISTOPATHOLOGY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; QUANTITATIVE DIAGNOSIS; REVIEW;

BRAIN; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED;

EID: 70349449873     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.83     Document Type: Review

References (243)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 343(13), 938-952 (2000).
2. Vrenken H, Geurts JJ. Gray and normal-appearing white matter in multiple sclerosis: an MRI perspective. Expert Rev. Neurother. 7(3), 271-279 (2007). • Brain tissue abnormalities in multiple sclerosis (MS) normal-appearing white and grey matter from an imaging perspective. (Pubitemid 46434175)
3. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr. Opin. Neurol. 15(3), 239-245 (2002). (Pubitemid 34596884)
4. Ormerod IE, Miller DH, McDonald WI et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions: a quantitative study. Brain 110(Pt 6), 1579-1616 (1987).
5. Miller DH, Rudge P, Johnson G et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 111 (Pt 4), 927-939 (1988). (Pubitemid 18200626)
6. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121(Pt 1), 3-24 (1998).
7. Brex PA, Ciccarelli O, O'Riordan JI et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346(3), 158-164 (2002). (Pubitemid 34438881)
8. Filippi M, Yousry T, Baratti C et al. Quantitative assessment of MRI lesion load in multiple sclerosis: a comparison of conventional spin-echo with fast fluidattenuated inversion recovery. Brain 119(Pt 4), 1349-1355 (1996). (Pubitemid 26300734)
9. Gawne-Cain ML, O'Riordan JI, Thompson AJ, Moseley IF, Miller DH. Multiple sclerosis lesion detection in the brain: a comparison of fast fluid-attenuated inversion recovery and conventional T2-weighted dual spin echo. Neurology 49(2), 364-370 (1997).
10. Le Bihan D, Turner R, Moonen CT, Pekar J. Imaging of diffusion and microcirculation with gradient sensitization: design, strategy, and significance. J. Magn. Reson. Imaging 1(1), 7-28 (1991).
11. Le Bihan D, Turner R, Douek P, Patronas N. Diffusion MR imaging: clinical applications. AJR Am. J. Roentgenol. 159(3), 591-599 (1992).
12. Horsfield MA, Lai M, Webb SL et al. Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. Magn. Reson. Med. 36(3), 393-400 (1996). (Pubitemid 26299265)
13. Werring DJ, Clark CA, Barker GJ, Thompson AJ, Miller DH. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology 52(8), 1626-1632 (1999).
14. Chenevert TL, Brunberg JA, Pipe JG. Anisotropic diffusion in human white matter: demonstration with MR techniques in vivo. Radiology 177(2), 401-405 (1990).
15. Beaulieu C, Allen PS. Determinants of anisotropic water diffusion in nerves. Magn. Reson. Med. 31(4), 394-400 (1994). (Pubitemid 24108269)
16. Pierpaoli C, Jezzard P, Basser PJ, Barnett A, Di Chiro G. Diffusion tensor MR imaging of the human brain. Radiology 201(3), 637-648 (1996). (Pubitemid 26392608)
17. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J. Magn. Reson. B. 111(3), 209-219 (1996). (Pubitemid 126758682)
18. Ciccarelli O, Werring DJ, Wheeler- Kingshott CA et al. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology 56(7), 926-933 (2001). (Pubitemid 32290810)
19. Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn. Reson. Med. 10(1), 135-144 (1989).
20. Filippi M, Grossman RI. MRI techniques to monitor MS evolution: the present and the future. Neurology 58(8), 1147-1153 (2002). (Pubitemid 34411856)
21. Dousset V, Grossman RI, Ramer KN et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 182(2), 483-491 (1992).
22. Kucharczyk W, Macdonald PM, Stanisz GJ, Henkelman RM. Relaxivity and magnetization transfer of white matter lipids at MR imaging: importance of cerebrosides and pH. Radiology 192(2), 521-529 (1994). (Pubitemid 24233938)
23. Deloire-Grassin MS, Brochet B, Quesson B et al. In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J. Neurol. Sci. 178(1), 10-16 (2000).
24. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann. Neurol. 56(3), 407-415 (2004). (Pubitemid 39166560)
25. Barkhof F, Bruck W, De Groot CJ et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol. 60(8), 1073-1081 (2003). (Pubitemid 36975794)
26. Cercignani M, Bozzali M, Iannucci G, Comi G, Filippi M. Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 70(3), 311-317 (2001). (Pubitemid 32250886)
27. Gareau PJ, Rutt BK, Karlik SJ, Mitchell JR. Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J. Magn. Reson. Imaging 11(6), 586-595 (2000).
28. MacKay A, Laule C, Vavasour I et al. Insights into brain microstructure from the T2 distribution. Magn. Reson. Imaging 24(4), 515-525 (2006).
29. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat. Rec. 265(2), 54-84 (2001).
30. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann. Neurol. 43(1), 56-71 (1998). (Pubitemid 28124649)
31. Davie CA, Barker GJ, Thompson AJ et al. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 63(6), 736-742 (1997).
32. Sarchielli P, Presciutti O, Pelliccioli GP et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 122(Pt 3), 513-521 (1999). (Pubitemid 29110525)
33. Davie CA, Barker GJ, Webb S et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 118(Pt 6), 1583-1592 (1995). (Pubitemid 26011926)
34. Cader S, Johansen-Berg H, Wylezinska M et al. Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis. Neuroimage 36(1), 19-27 (2007). (Pubitemid 46617958)
35. Chard DT, Griffin CM, McLean MA et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125(Pt 10), 2342-2352 (2002).
36. Kapeller P, Brex PA, Chard D et al. Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult. Scler. 8(3), 207-210 (2002). (Pubitemid 34654055)
37. Stewart WA, Hall LD, Berry K, Paty DW. Correlation between NMR scan and brain slice data in multiple sclerosis. Lancet 2(8399), 412 (1984). (Pubitemid 14068543)
38. Kermode AG, Thompson AJ, Tofts P et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. pathogenetic and clinical implications. Brain 113(Pt 5), 1477-1489 (1990). (Pubitemid 20385925)
39. Bastianello S, Pozzilli C, Bernardi S et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 40(4), 591-595 (1990). (Pubitemid 20139082)
40. McFarland HF. The emerging role of MRI in multiple sclerosis and the new diagnostic criteria. Mult. Scler. 8(1), 71-72 (2002). • Impact of MRI methods for understanding MS pathology and assessing new therapies.
41. Ciccarelli O, Giugni E, Paolillo A et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur. J. Neurol. 6(4), 455-459 (1999). (Pubitemid 29371143)
42. He J Grossman RI, Ge Y, Mannon LJ. Enhancing patterns in multiple sclerosis: evolution and persistence. AJNR Am. J. Neuroradiol. 22(4), 664-669 (2001). (Pubitemid 32318693)
43. Rovira A, Alonso J, Cucurella G et al. Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. AJNR Am. J. Neuroradiol. 20(10), 1939-1945 (1999).
44. van Waesberghe JH, van Walderveen MA, Castelijns JA et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am. J. Neuroradiol. 19(4), 675-683 (1998).
45. Katz D, Taubenberger JK, Cannella B et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann. Neurol. 34(5), 661-669 (1993). (Pubitemid 23333237)
46. van Walderveen MA, Kamphorst W, Scheltens P et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50(5), 1282-1288 (1998). (Pubitemid 28240340)
47. van Walderveen MA, Barkhof F, Hommes OR et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 45(9), 1684-1690 (1995).
48. Truyen L, van Waesberghe JH, van Walderveen MA et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47(6), 1469-1476 (1996). (Pubitemid 26422538)
49. Giugni E, Pozzilli C, Bastianello S et al. MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. Mult. Scler. 3(4), 221-225 (1997). (Pubitemid 27478585)
50. Barkhof F, McGowan JC, van Waesberghe JH, Grossman RI. Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. J. Neurol. Neurosurg. Psychiatry 64(Suppl. 1), S77-S79 (1998). (Pubitemid 28274442)
51. Bagnato F, Jeffries N, Richert ND et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 126(Pt 8), 1782-1789 (2003). • Longitudinal study on the 4-year evolution of black holes and their relationship with contrast-enhancing lesions. (Pubitemid 36917337)
52. Patrikios P, Stadelmann C, Kutzelnigg A et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129(Pt 12), 3165-3172 (2006). (Pubitemid 44871433)
53. Di Perri C, Dwyer MG, Wack DS et al. Signal abnormalities on 1.5 and 3 tesla brain MRI in multiple sclerosis patients and healthy controls: a morphological and spatial quantitative comparison study. Neuroimage 47(4) 1352-1362 (2009).
54. Thompson AJ, Miller D, Youl B et al. Serial gadolinium-enhanced MRI in relapsing/ remitting multiple sclerosis of varying disease duration. Neurology 42(1), 60-63 (1992).
55. Kappos L, Weinshenker B, Pozzilli C et al. Interferon β-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63(10), 1779-1787 (2004). (Pubitemid 39532369)
56. Thompson AJ, Kermode AG, Wicks D et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann. Neurol. 29(1), 53-62 (1991). • Serial MRI study on the difference in the dynamics of disease activity between the two forms of progressive MS, particularly in relation to the inflammatory component of the lesions.
57. Pozzilli C, Tomassini V, Marinelli F et al. 'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence. Eur. J. Neurol. 10(1), 95-97 (2003). (Pubitemid 36114952)
58. Barkhof F, Rocca M, Francis G et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a. Ann. Neurol. 53(6), 718-724 (2003). (Pubitemid 36622508)
59. Tortorella C, Bellacosa A, Paolicelli D et al. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. J. Neurol. Sci. 239(1), 95-99 (2005). (Pubitemid 41617420)
60. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF, Serial gadoliniumenhanced magnetic resonance imaging scans in patients with early, relapsing- remitting multiple sclerosis: implications for clinical trials and natural history. Ann. Neurol. 29(5), 548-555 (1991).
61. Grossman RI, Gonzalez-Scarano F, Atlas SW, Galetta S, Silberberg DH. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 161(3), 721-725 (1986). (Pubitemid 17200424)
62. Kappos L, Moeri D, Radue EW et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis: Gadolinium MRI Meta-Analysis Group. Lancet 353(9157), 964-969 (1999). (Pubitemid 29132605)
63. Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60(4), 640-646 (2003). (Pubitemid 36246083)
64. Minneboo A, Uitdehaag BM, Ader HJ et al. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology 65(1), 56-61 (2005). (Pubitemid 40967776)
65. Filippi M, Rocca MA, Comi G. Magnetization transfer ratios of multiple sclerosis lesions with variable durations of enhancement. J. Neurol. Sci. 159(2), 162-165 (1998). (Pubitemid 28384523)
66. McFarland HF, Frank JA, Albert PS et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann. Neurol. 32(6), 758-766 (1992).
67. Trapp BD, Peterson J, Ransohoff RM et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338(5), 278-285 (1998). (Pubitemid 28065253)
68. Lucchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47(6), 707-717 (2000). (Pubitemid 30390191)
69. Storch M, Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr. Opin. Neurol. 10(3), 186-192 (1997).
70. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55(4), 458-468 (2004).
71. De Stefano N, Matthews PM, Fu L et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a Longitudinal Magnetic Resonance Spectroscopy study. Brain 121(Pt8), 1469-1477 (1998). (Pubitemid 28349900)
72. Sailer M, Losseff NA, Wang L et al. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study. Eur. J. Neurol. 8(1), 37-42 (2001). (Pubitemid 32154572)
73. Morgen K, Jeffries NO, Stone R et al. Ring-enchancement in multiple sclerosis: marker of disease severity. Mult. Scler. 7(3), 167-171 (2001). (Pubitemid 32651816)
74. Pozzilli C, Falaschi P, Mainero C et al. MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns. Neurology 53(3), 622-624 (1999). (Pubitemid 29382062)
75. Filippi M. In vivo tissue characterization of multiple sclerosis and other white matter diseases using magnetic resonance based techniques. J. Neurol. 248(12), 1019-1029 (2001). (Pubitemid 34134536)
76. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 56(3), 304-311 (2001). (Pubitemid 32144139)
77. Davie CA, Hawkins CP, Barker GJ et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117(Pt 1), 49-58 (1994).
78. De Stefano N, Matthews PM, Antel JP et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann. Neurol. 38(6), 901-909 (1995). (Pubitemid 26004072)
79. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann. Neurol. 31(3), 235-241 (1992).
80. De Stefano N, Matthews PM, Arnold DL, Reversible decreases in N-acetylaspartate after acute brain injury. Magn. Reson. Med. 34(5), 721-727 (1995).
81. Barnes D, Munro PM, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion: a quantitative MRI and electron microscopic study. Brain 114(Pt 3), 1271-1280 (1991).
82. Silver NC, Tofts PS, Symms MR et al. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult. Scler. 7(2), 75-82 (2001).
83. Pozzilli C, Bernardi S, Mansi L et al. Quantitative assessment of blood-brain barrier permeability in multiple sclerosis using 68-Ga-EDTA and positron emission tomography. J. Neurol. Neurosurg. Psychiatry 51(8), 1058-1062 (1988). (Pubitemid 18195767)
84. Lucchinetti CF, Gavrilova RH, Metz I et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131(Pt 7), 1759-1775 (2008). (Pubitemid 351957454)
85. Paty DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can. J. Neurol. Sci. 15(3), 266-272 (1988).
86. Filippi M, Linking structural, metabolic and functional changes in multiple sclerosis. Eur. J. Neurol. 8(4), 291-297 (2001). (Pubitemid 32612891)
87. Molyneux PD, Filippi M, Barkhof F et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann. Neurol. 43(3), 332-339 (1998). (Pubitemid 28113596)
88. Lee MA, Smith S, Palace J, Matthews PM. Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging. Brain 121(Pt 11), 2095-2102 (1998). (Pubitemid 28497907)
89. Thompson AJ, Polman CH, Miller DH et al. Primary progressive multiple sclerosis. Brain 120(Pt 6), 1085-1096 (1997).
90. Rovaris M, Bozzali M, Santuccio G et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 124(Pt 12), 2540-2549 (2001). (Pubitemid 33134941)
91. Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 126(Pt 11), 2528-2536 (2003).
92. Evangelou N, Konz D, Esiri MM et al. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 123(Pt 9), 1845-1849 (2000).
93. Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 123(Pt 2), 308-317 (2000). (Pubitemid 30055154)
94. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14(3), 271-278 (2001). (Pubitemid 32510589)
95. Pelletier D, Nelson SJ, Oh J et al. MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy. J. Neurol. Neurosurg. Psychiatry 74(7), 950-952 (2003). (Pubitemid 36783003)
96. Rocca MA, Iannucci G, Rovaris M, Comi G, Filippi M. Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions - a diffusion tensor MR study. J. Neurol. 250(4), 456-460 (2003). (Pubitemid 36459753)
97. Lee MA, Smith S, Palace J et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain 122(Pt 7), 1261-1270 (1999). (Pubitemid 29324847)
98. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58(6), 840-846 (2005).
99. Tubridy N, Barker GJ, Macmanus DG, Moseley IF, Miller DH. Three-dimensional fast fluid attenuated inversion recovery (3D fast FLAIR), a new MRI sequence which increases the detectable cerebral lesion load in multiple sclerosis. Br. J. Radiol. 71(848), 840-845 (1998). (Pubitemid 28391084)
100. Filippi M, Rocca MA, Horsfield MA, Comi G. A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: correlations with changes of T2 and magnetization transfer lesion loads. J. Neurol. Sci. 158(2), 203-208 (1998). (Pubitemid 28342085)
101. Pike GB, De Stefano N, Narayanan S et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology 215(3), 824-830 (2000). (Pubitemid 30346024)
102. Werring DJ, Brassat D, Droogan AG et al. The pathogenesis of lesions and normalappearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 123(Pt 8), 1667-1676 (2000). • Imaging study showing that structural damage in lesions causes damage or dysfunction in connected areas of normal-appearing white matter. (Pubitemid 30481190)
103. Wuerfel J, Bellmann-Strobl J, Brunecker P et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 127(Pt 1), 111-119 (2004). (Pubitemid 38055350)
104. Bruck W, Bitsch A, Kolenda H et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neurol. 42(5), 783-793 (1997). (Pubitemid 27481551)
105. van Waesberghe JH, Kamphorst W, De Groot CJ et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann. Neurol. 46(5), 747-754 (1999). (Pubitemid 29518136)
106. Bitsch A, Kuhlmann T, Stadelmann C et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann. Neurol. 49(6), 793-796 (2001). (Pubitemid 32530247)
107. Tomassini V, Paolillo A, Russo P et al. Predictors of long-term clinical response to interferon β therapy in relapsing multiple sclerosis. J. Neurol. 253(3), 287-293 (2006).
108. Nijeholt GJ, van Walderveen MA, Castelijns JA et al. Brain and spinal cord abnormalities in multiple sclerosis: correlation between MRI parameters, clinical subtypes and symptoms. Brain 121(Pt 4), 687-697 (1998).
109. Bitsch A, Bruhn H, Vougioukas V et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am. J. Neuroradiol. 20(9), 1619-1627 (1999). (Pubitemid 29498612)
110. van Walderveen MA, Barkhof F, Pouwels PJ et al. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann. Neurol. 46(1), 79-87 (1999). (Pubitemid 29314385)
111. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 120(Pt 3), 393-399 (1997). (Pubitemid 27153632)
112. Dousset V, Gayou A, Brochet B, Caille JM. Early structural changes in acute MS lesions assessed by serial magnetization transfer studies. Neurology 51(4), 1150-1155 (1998). (Pubitemid 28473417)
113. van Walderveen MA, Truyen L, van Oosten BW et al. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity. Arch Neurol. 56(3), 345-351 (1999). (Pubitemid 29120233)
114. Caruso A, Di Giorgi Gerevini V, Castiglione M et al. Testosterone amplifies excitotoxic damage of cultured oligodendrocytes. J. Neurochem. 88(5), 1179-1185 (2004). (Pubitemid 38280685)
115. Tomassini V, Onesti E, Mainero C et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J. Neurol. Neurosurg. Psychiatry 76(2), 272-275 (2005). (Pubitemid 40143725)
116. Enzinger C, Ropele S, Smith S et al. Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4. Ann. Neurol. 55(4), 563-569 (2004). • Imaging evidence of the genetic influence on tissue damage in MS. (Pubitemid 38391974)
117. Drayer BP, Burger P, Hurwitz B et al. Magnetic resonance imaging in multiple sclerosis: decreased signal in thalamus and putamen. Ann. Neurol. 22(4), 546-550 (1987). (Pubitemid 17164782)
118. Pujol J, Junque C, Vendrell P et al. Biological significance of iron-related magnetic resonance imaging changes in the brain. Arch Neurol. 49(7), 711-717 (1992).
119. Bakshi R, Benedict RH, Bermel RA et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol. 59(1), 62-68 (2002). (Pubitemid 34052557)
120. Schwartz KM, Erickson BJ, Lucchinetti C. Pattern of T2 hypointensity associated with ring-enhancing brain lesions can help to differentiate pathology. Neuroradiology 48(3), 143-149 (2006). (Pubitemid 43380226)
121. Haacke EM, Makki M, Ge Y et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J. Magn. Reson. Imaging 29(3), 537-544 (2009).
122. Hammond KE, Metcalf M, Carvajal L et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann. Neurol. 64(6), 707-713 (2008).
123. Vellinga MM, Oude Engberink RD, Seewann A et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 131(Pt 3), 800-807 (2008). (Pubitemid 351294725)
124. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 25, 315-320 (1962).
125. Bo L, Geurts JJ, van der Valk P, Polman C, Barkhof F. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol. 64(1), 76-80 (2007). (Pubitemid 46072427)
126. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 9(4), 323-331 (2003). (Pubitemid 36958014)
127. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50(3), 389-400 (2001). • Histopathological study suggesting differences between grey and white matter pathology. (Pubitemid 32848742)
128. Amato MP, Bartolozzi ML, Zipoli V et al. Neocortical volume decrease in relapsing- remitting MS patients with mild cognitive impairment. Neurology 63(1), 89-93 (2004). (Pubitemid 38943784)
129. Kidd D, Barkhof F, McConnell R et al. Cortical lesions in multiple sclerosis. Brain 122(Pt 1), 17-26 (1999). • Neuropathological and MRI study on the prevalence and distribution of cortical lesions.
130. Kutzelnigg A, Lucchinetti CF, Stadelmann C et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128(Pt 11), 2705-2712 (2005). (Pubitemid 41552953)
131. Geurts JJ, Bo L, Roosendaal SD et al. Extensive hippocampal demyelination in multiple sclerosis. J. Neuropathol. Exp. Neurol. 66(9), 819-827 (2007). (Pubitemid 47360957)
132. Vercellino M, Plano F, Votta B et al. Grey matter pathology in multiple sclerosis. J. Neuropathol. Exp. Neurol. 64(12), 1101-1107 (2005). (Pubitemid 43755403)
133. Huitinga I, De Groot CJ, Van der Valk P et al. Hypothalamic lesions in multiple sclerosis. J. Neuropathol. Exp. Neurol. 60(12), 1208-1218 (2001).
134. Gilmore CP, Bo L, Owens T et al. Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology. Brain Pathol. 16(3), 202-208 (2006). (Pubitemid 44175234)
135. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 67(6), 960-967 (2006). (Pubitemid 44454585)
136. Geurts JJ, Barkhof F, Grey matter pathology in multiple sclerosis. Lancet Neurol. 7(9), 841-851 (2008).
137. Geurts JJ, Bo L, Pouwels PJ et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am. J. Neuroradiol. 26(3), 572-577 (2005). (Pubitemid 43085960)
138. Geurts JJ, Pouwels PJ, Uitdehaag BM et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 236(1), 254-260 (2005).
139. Bagnato F, Butman JA, Gupta S et al. In vivo detection of cortical plaques by MR imaging in patients with multiple sclerosis. AJNR Am. J. Neuroradiol. 27(10), 2161-2167 (2006). (Pubitemid 44788650)
140. Calabrese M, De Stefano N, Atzori M et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol. 64(10), 1416-1422 (2007). (Pubitemid 47572665)
141. Calabrese M, Rocca MA, Atzori M et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 72(15), 1330-1336 (2009).
142. Sailer M, Fischl B, Salat D et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 126(Pt 8), 1734-1744 (2003). (Pubitemid 36917333)
143. Wegner C, Matthews PM. A new view of the cortex, new insights into multiple sclerosis. Brain 126(Pt 8), 1719-1721 (2003). (Pubitemid 36917331)
144. Calabrese M, Filippi M, Rovaris M et al. Morphology and evolution of cortical lesions in multiple sclerosis: a longitudinal MRI study. Neuroimage 42(4), 1324-1328 (2008).
145. Kollia K, Maderwald S, Putzki N et al. First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T. AJNR Am. J. Neuroradiol. 30(4), 699-702 (2009).
146. Kangarlu A, Bourekas EC, Ray-Chaudhury A, Rammohan KW. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am. J. Neuroradiol. 28(2), 262-266 (2007). (Pubitemid 46281042)
147. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J. Neurol. Sci. 41(1), 81-91 (1979).
148. Chard D, Miller D. Is multiple sclerosis a generalized disease of the central nervous system? An MRI perspective. Curr. Opin. Neurol.22(3), 214-218 (2009).
149. Rashid W, Parkes LM, Ingle GT et al. Abnormalities of cerebral perfusion in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 75(9), 1288-1293 (2004). (Pubitemid 39141335)
150. Laule C, Vavasour IM, Moore GR et al. Water content and myelin water fraction in multiple sclerosis. A T2 relaxation study. J. Neurol. 251(3), 284-293 (2004). (Pubitemid 38387145)
151. Ciccarelli O, Werring DJ, Barker GJ et al. A study of the mechanisms of normalappearing white matter damage in multiple sclerosis using diffusion tensor imaging - evidence of Wallerian degeneration. J. Neurol. 250(3), 287-292 (2003). (Pubitemid 36399267)
152. Cercignani M, Inglese M, Pagani E, Comi G, Filippi M. Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. AJNR Am. J. Neuroradiol. 22(5), 952-958 (2001). (Pubitemid 32436241)
153. Filippi M, Inglese M, Rovaris M et al. Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. Neurology 55(7), 940-946 (2000). (Pubitemid 30764354)
154. Tortorella C, Viti B, Bozzali M et al. A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology 54(1), 186-193 (2000). (Pubitemid 30038758)
155. Traboulsee A, Dehmeshki J, Brex PA et al. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology 59(1), 126-128 (2002). (Pubitemid 34742808)
156. De Stefano N, Iannucci G, Sormani MP et al. MR correlates of cerebral atrophy in patients with multiple sclerosis. J. Neurol. 249(8), 1072-1077 (2002). (Pubitemid 35002232)
157. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann. Neurol. 47(3), 391-395 (2000). (Pubitemid 30141854)
158. Filippi M, Iannucci G, Tortorella C et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 52(3), 588-594 (1999). (Pubitemid 29075609)
159. Cercignani M, Iannucci G, Rocca MA et al. Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI. Neurology 54(5), 1139-1144 (2000). (Pubitemid 30151859)
160. Filippi M, Campi A, Dousset V et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 45(3 Pt 1), 478-482 (1995). (Pubitemid 27132813)
161. Griffin CM, Chard DT, Parker GJ et al. The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis. J. Neurol. 249(2), 193-199 (2002).
162. Iannucci G, Tortorella C, Rovaris M et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am. J. Neuroradiol. 21(6), 1034-1038 (2000). (Pubitemid 30390538)
163. Leary SM, Silver NC, Stevenson VL et al. Magnetisation transfer of normal appearing white matter in primary progressive multiple sclerosis. Mult. Scler. 5(5), 313-316 (1999).
164. Loevner LA, Grossman RI, Cohen JA et al. Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis: assessment with magnetization-transfer measurements. Radiology 196(2), 511-515 (1995).
165. Parry A, Clare S, Jenkinson M et al. White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis. J. Neurol. 249(9), 1279-1286 (2002). (Pubitemid 35025108)
166. Rovaris M, Bozzali M, Santuccio G et al. Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. J. Neurol. Neurosurg. Psychiatry 69(6), 723-727 (2000).
167. Vaithianathar L, Tench CR, Morgan PS, Wilson M, Blumhardt LD. T1 relaxation time mapping of white matter tracts in multiple sclerosis defined by diffusion tensor imaging. J. Neurol. 249(9), 1272-1278 (2002). (Pubitemid 35025107)
168. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann. Neurol. 43(6), 809-814 (1998). (Pubitemid 28280225)
169. Goodkin DE, Rooney WD, Sloan R et al. A serial study of new MS lesions and the white matter from which they arise. Neurology 51(6), 1689-1697 (1998). (Pubitemid 28565254)
170. Rocca MA, Cercignani M, Iannucci G, Comi G, Filippi M. Weekly diffusionweighted imaging of normal-appearing white matter in MS. Neurology 55(6), 882-884 (2000). (Pubitemid 30727736)
171. Fazekas F, Ropele S, Enzinger C, Seifert T, Strasser-Fuchs S. Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis. Mult. Scler. 8(6), 479-484 (2002). (Pubitemid 35396396)
172. De Stefano N, Narayanan S, Matthews PM et al. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 122(Pt 10), 1933-1939 (1999).
173. Bergers E, Bot JC, De Groot CJ et al. Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology 59(11), 1766-1771 (2002). (Pubitemid 35424460)
174. Ganter P, Prince C, Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol. Appl. Neurobiol. 25(6), 459-467 (1999). (Pubitemid 30045420)
175. Nijeholt GJ, Bergers E, Kamphorst W et al. Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype. Brain 124(Pt 1), 154-166 (2001). (Pubitemid 32055997)
176. Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am. J. Neuroradiol. 23(6), 985-988 (2002). (Pubitemid 34663445)
177. Ge Y, Grossman RI, Udupa JK et al. Magnetization transfer ratio histogram analysis of gray matter in relapsing- remitting multiple sclerosis. AJNR Am. J. Neuroradiol. 22(3), 470-475 (2001). (Pubitemid 32221410)
178. Ge Y, Grossman RI, Udupa JK et al. Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Radiology 220(3), 606-610 (2001). (Pubitemid 32799964)
179. Kapeller P, McLean MA, Griffin CM et al. Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J. Neurol. 248(2), 131-138 (2001). (Pubitemid 32245424)
180. Sharma R, Narayana PA, Wolinsky JS. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult. Scler. 7(4), 221-226 (2001). (Pubitemid 32780691)
181. Dehmeshki J, Chard DT, Leary SM et al. The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J. Neurol. 250(1), 67-74 (2003). (Pubitemid 36206687)
182. Chard DT, Griffin CM, Parker GJ et al. Brain atrophy in clinically early relapsing- remitting multiple sclerosis. Brain 125(Pt 2), 327-337 (2002).
183. Rovaris M, Iannucci G, Falautano M et al. Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J. Neurol. Sci. 195(2), 103-109 (2002). (Pubitemid 34202286)
184. Paolillo A, Pozzilli C, Gasperini C et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability. J. Neurol. Sci. 174(2), 85-91 (2000).
185. Paolillo A, Piattella MC, Pantano P et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J. Neurol. 251(4), 432-439 (2004). (Pubitemid 38501301)
186. Filippi M, Rovaris M, Inglese M et al. Interferon β-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebocontrolled trial. Lancet 364(9444), 1489-1496 (2004). (Pubitemid 39410414)
187. Chard DT, Brex PA, Ciccarelli O et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J. Neurol. Neurosurg. Psychiatry 74(11), 1551-1554 (2003). (Pubitemid 37392879)
188. Kalkers NF, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F. Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. Mult. Scler. 8(5), 410-414 (2002). (Pubitemid 35041460)
189. Bakshi R, Dmochowski J, Shaikh ZA, Jacobs L. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J. Neurol. Sci. 185(1), 19-26 (2001). (Pubitemid 32215497)
190. Bermel RA, Puli SR, Rudick RA et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch. Neurol. 62(9), 1371-1376 (2005).
191. O'Riordan JI, Thompson AJ, Kingsley DP et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121(Pt 3), 495-503 (1998).
192. Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120(Pt 11), 2059-2069 (1997). (Pubitemid 27493740)
193. Morrissey SP, Miller DH, Kendall BE et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 116(Pt 1), 135-146 (1993).
194. Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131(Pt 3), 808-817 (2008).
195. Charil A, Zijdenbos AP, Taylor J et al. Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets. Neuroimage 19(3), 532-544 (2003). (Pubitemid 36918200)
196. Youl BD, Turano G, Miller DH et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain 114(Pt 6), 2437-2450 (1991).
197. Thorpe JW, Kidd D, Moseley IF et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing- remitting multiple sclerosis. Neurology 46(2), 373-378 (1996). (Pubitemid 26081316)
198. Vellinga MM, Geurts JJ, Rostrup E et al. Clinical correlations of brain lesion distribution in multiple sclerosis. J. Magn. Reson. Imaging 29(4), 768-773 (2009).
199. Ciccarelli O, Brex PA, Thompson AJ, Miller DH. Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR. J. Neurol. 249(1), 18-24 (2002). (Pubitemid 34119019)
200. Li DK, Held U, Petkau J et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66(9), 1384-1389 (2006). (Pubitemid 43739648)
201. Goodin DS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann. Neurol. 59(4), 597-605 (2006).
202. Miki Y, Grossman RI, Udupa JK et al. Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images - lack of correlation between changes in T2 lesion volume and clinical findings. Radiology 213(2), 395-399 (1999). (Pubitemid 29510584)
203. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann. Neurol. 60(2), 236-242 (2006). (Pubitemid 44182398)
204. Barkhof F, Filippi M. MRI - the perfect surrogate marker for multiple sclerosis? Nat. Rev. Neurol. 5(4), 182-183 (2009).
205. Reddy H, Narayanan S, Matthews PM et al. Relating axonal injury to functional recovery in MS. Neurology 54(1), 236-239 (2000). (Pubitemid 30038770)
206. Lee M, Reddy H, Johansen-Berg H et al. The motor cortex shows adaptive functional changes to brain injury from multiple sclerosis. Ann. Neurol. 47(5), 606-613 (2000). (Pubitemid 30261896)
207. Reddy H, Narayanan S, Arnoutelis R et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 123(Pt 11), 2314-2320 (2000). (Pubitemid 30823946)
208. Pantano P, Mainero C, Iannetti GD et al. Contribution of corticospinal tract damage to cortical motor reorganization after a single clinical attack of multiple sclerosis. Neuroimage 17(4), 1837-1843 (2002).
209. Rocca MA, Agosta F, Martinelli V et al. The level of spinal cord involvement influences the pattern of movementassociated cortical recruitment in patients with isolated myelitis. Neuroimage 30(3), 879-884 (2006).
210. Mainero C, De Stefano N, Iannucci G et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology 56(10), 1331-1334 (2001). (Pubitemid 32455293)
211. Kalkers NF, Bergers L, de Groot V et al. Concurrent validity of the MS functional composite using MRI as a biological disease marker. Neurology 56(2), 215-219 (2001). (Pubitemid 32095363)
212. Mikaeloff Y, Adamsbaum C, Husson B et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 127(Pt 9), 1942-1947 (2004).
213. Korteweg T, Tintore M, Uitdehaag B et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol. 5(3), 221-227 (2006). (Pubitemid 43238345)
214. Balassy C, Bernert G, Wober-Bingol C et al. Long-term MRI observations of childhood-onset relapsing-remitting multiple sclerosis. Neuropediatrics 32(1), 28-37 (2001). (Pubitemid 32290432)
215. McAdam LC, Blaser SI, Banwell BL. Pediatric tumefactive demyelination: case series and review of the literature. Pediatr. Neurol. 26(1), 18-25 (2002).
216. Mezzapesa DM, Rocca MA, Falini A et al. A preliminary diffusion tensor and magnetization transfer magnetic resonance imaging study of early-onset multiple sclerosis. Arch Neurol. 61(3), 366-368 (2004). (Pubitemid 38327354)
217. Tortorella P, Rocca MA, Mezzapesa DM et al. MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis. J. Neurol. 253(7), 903-907 (2006). (Pubitemid 44100444)
218. Hahn CD, Shroff MM, Blaser SI, Banwell BL. MRI criteria for multiple sclerosis: evaluation in a pediatric cohort. Neurology 62(5), 806-808 (2004).
219. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult. Scler. 8(1), 40-51 (2002). (Pubitemid 34193027)
220. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebocontrolled study of interferon-β1a in relapsing-remitting multiple sclerosis: prevention of relapses and disability by interferon-β1a subcutaneously in multiple sclerosis. Ann. Neurol. 46(2), 197-206 (1999).
221. Paty DW, Li DK. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI study group and the IFNB Multiple Sclerosis study group. Neurology 43(4), 662-667 (1993).
222. Simon JH, Jacobs LD, Campion M et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis: The Multiple Sclerosis Collaborative research group. Ann. Neurol. 43(1), 79-87 (1998).
223. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebocontrolled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis: European/Canadian Glatiramer Acetate study group. Ann. Neurol. 49(3), 290-297 (2001). (Pubitemid 32202781)
224. Pozzilli C, Marinelli F, Romano S, Bagnato F. Corticosteroids treatment. J. Neurol. Sci. 223(1), 47-51 (2004).
225. Bagnato F, Evangelou IE, Gallo A, Gaindh D, Yao K. The effect of interferon-β on black holes in patients with multiple sclerosis. Expert Opin. Biol. Ther. 7(7), 1079-1091 (2007). (Pubitemid 47204360)
226. Rovaris M, Capra R, Martinelli V et al. Cumulative effect of a weekly low dose of interferon β 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. J. Neurol. Sci. 171(2), 130-134 (1999). (Pubitemid 29420713)
227. Stone LA, Frank JA, Albert PS et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol. 37(5), 611-619 (1995).
228. Pozzilli C, Bastianello S, Koudriavtseva T et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 61(3), 251-258 (1996). (Pubitemid 26293719)
229. Miller DH, Molyneux PD, Barker GJ et al. Effect of interferon-β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial: European study group on interferon-β1b in secondary progressive multiple sclerosis. Ann. Neurol. 46(6), 850-859 (1999).
230. Paolillo A, Bastianello S, Frontoni M et al. Magnetic resonance imaging outcome of new enhancing lesions in relapsing- remitting multiple sclerosis patients treated with interferon β1a. J. Neurol. 246(6), 443-448 (1999). (Pubitemid 29326837)
231. Miller DH, Soon D, Fernando KT et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68(17), 1390-1401 (2007). (Pubitemid 46659091)
232. Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry 62(2), 112-118 (1997). (Pubitemid 27090928)
233. Krapf H, Morrissey SP, Zenker O et al. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 65(5), 690-695 (2005). (Pubitemid 41285846)
234. Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur. J. Paediatr. Neurol. 13(1), 67-71 (2009).
235. Huppke P, Stark W, Zurcher C et al. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 65(12), 1655-1658 (2008).
236. The Once Weekly Interferon for MS Study Group. Evidence of IFN-β-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 53, 679 (1999).
237. Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the evidence trial. Neurology 59(10), 1496-1506 (2002). (Pubitemid 35387053)
238. Durelli L, Verdun E, Barbero P et al. Every-other-day interferon β-1b versus once-weekly interferon β-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359(9316), 1453-1460 (2002). (Pubitemid 34457761)
239. Bagnato F, Gupta S, Richert ND et al. Effects of interferon β-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch. Neurol. 62(11), 1684-1688 (2005). (Pubitemid 41626663)
240. Barkhof F, van Waesberghe JH, Filippi M et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon β-1b treatment. Brain 124(Pt 7), 1396-1402 (2001). (Pubitemid 32606100)
241. Filippi M, Rovaris M, Rocca MA et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 57(4), 731-733 (2001).
242. Brex PA, Molyneux PD, Smiddy P et al. The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 57(12), 2185-2190 (2001). (Pubitemid 34016449)
243. Bruck W. Clinical implications of neuropathological findings in multiple sclerosis. J. Neurol. 252(Suppl. 3), III10-III14 (2005). (Pubitemid 41355779)